Team:IONIS-PARIS/Entrepreneurship/overview
Overview
This entrepreneurship part was made in order to bring our technology to the industrial scale.
It contains the following sections: fundraising and communication, market study and public opinion, and the projected final product.
Our team worked on demonstrating the possible place of a GMO product in France.
Actually, the French population does not have a very positive opinion about GMOs. However, we managed to communicate on our project
with people who could be future consumers, with our identified clients such as winemakers, and with professionals from private companies.
The aim was to get a global view of our project: firstly, in knowing exactly what were the expectations of winemakers; secondly,
in taking into account the French population’s point of view, and thirdly, in examining the geographical areas in need to improve
French wine production. We also had to analyse our possible competitors.
Find more information on the Market Study page.
2017 April frosts in France
Do you think agriculture in your country suffers from global warming?
Overview of the Kickstarter Campaign
Picture 1: Meeting with M.Bocquet
Our project needed financing and advertising, so we tried several different fundraising sources. We first contacted public and private sector groups, and also benefited from our school’s help. Finally, we launched our crowdfunding on Kickstarter from August to October 2017. You can get a complete list of all our sponsors by clicking here Regarding the communication part, we were very active on social networks, and organised a lot of meetings with professionals to talk about our project and gather advice on how we could develop it.
To study the way we raised funds and communicated about Softer Shock, you can check out the Fundraising and Communication report available on the dedicated page!
We had positive feedback about our project but the GMO problem was the main concern. We therefore had to find another idea to promote our product at an industrial scale. We decided to keep our modified microorganism, and to put it in a contained system, which is the norm in the medical sector, as it is done with the recombinant protein production, for example.
On the left is illustrated the kind of bioreactor we intend to use to produce our product at an industrial scale.
If you wish to get more information about this contained system, do not hesitate to read our perspectives page.
